Gilead Sciences, Inc. (LON:0QYQ)

Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of GBP 118.64 billion. The enterprise value is 129.60 billion.

Market Cap	118.64B
Enterprise Value	129.60B

Important Dates

The last earnings date was Thursday, October 30, 2025.

Earnings Date	Oct 30, 2025
Ex-Dividend Date	Sep 15, 2025

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	+1.02%
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.09%
Owned by Institutions (%)	88.19%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 19.66 and the forward PE ratio is 15.04.

PE Ratio	19.66
Forward PE	15.04
PS Ratio	5.48
PB Ratio	7.43
P/TBV Ratio	n/a
P/FCF Ratio	17.41
P/OCF Ratio	16.50
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.87, with an EV/FCF ratio of 19.01.

EV / Earnings	21.48
EV / Sales	5.84
EV / EBITDA	11.87
EV / EBIT	14.93
EV / FCF	19.01

Financial Position

The company has a current ratio of 1.45, with a Debt / Equity ratio of 1.16.

Current Ratio	1.45
Quick Ratio	1.10
Debt / Equity	1.16
Debt / EBITDA	1.74
Debt / FCF	2.72
Interest Coverage	11.17

Financial Efficiency

Return on equity (ROE) is 40.71% and return on invested capital (ROIC) is 16.14%.

Return on Equity (ROE)	40.71%
Return on Assets (ROA)	12.57%
Return on Invested Capital (ROIC)	16.14%
Return on Capital Employed (ROCE)	24.59%
Revenue Per Employee	1.23M
Profits Per Employee	342,804
Employee Count	17,600
Asset Turnover	0.51
Inventory Turnover	3.39

Taxes

In the past 12 months, Gilead Sciences has paid 1.32 billion in taxes.

Income Tax	1.32B
Effective Tax Rate	17.96%

Stock Price Statistics

The stock price has increased by +41.46% in the last 52 weeks. The beta is 0.33, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.33
52-Week Price Change	+41.46%
50-Day Moving Average	118.68
200-Day Moving Average	112.32
Relative Strength Index (RSI)	58.40
Average Volume (20 Days)	4,667

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.49

Income Statement

In the last 12 months, Gilead Sciences had revenue of GBP 21.64 billion and earned 6.03 billion in profits. Earnings per share was 4.78.

Revenue	21.64B
Gross Profit	17.03B
Operating Income	8.46B
Pretax Income	7.35B
Net Income	6.03B
EBITDA	10.52B
EBIT	8.46B
Earnings Per Share (EPS)	4.78

Balance Sheet

The company has 6.32 billion in cash and 18.55 billion in debt, giving a net cash position of -10.75 billion.

Cash & Cash Equivalents	6.32B
Total Debt	18.55B
Net Cash	-10.75B
Net Cash Per Share	n/a
Equity (Book Value)	15.96B
Book Value Per Share	12.90
Working Capital	4.15B

Cash Flow

In the last 12 months, operating cash flow was 7.19 billion and capital expenditures -375.69 million, giving a free cash flow of 6.82 billion.

Operating Cash Flow	7.19B
Capital Expenditures	-375.69M
Free Cash Flow	6.82B
FCF Per Share	n/a

Margins

Gross margin is 78.72%, with operating and profit margins of 39.09% and 27.88%.

Gross Margin	78.72%
Operating Margin	39.09%
Pretax Margin	33.99%
Profit Margin	27.88%
EBITDA Margin	48.60%
EBIT Margin	39.09%
FCF Margin	31.50%

Dividends & Yields

This stock pays an annual dividend of 2.38, which amounts to a dividend yield of 1.87%.

Dividend Per Share	2.38
Dividend Yield	1.87%
Dividend Growth (YoY)	-0.02%
Years of Dividend Growth	3
Payout Ratio	49.10%
Buyback Yield	-1.02%
Shareholder Yield	0.85%
Earnings Yield	5.09%
FCF Yield	5.75%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.64 and a Piotroski F-Score of 7.

Altman Z-Score	3.64
Piotroski F-Score	7